Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration
Expert Review of Pharmacoeconomics & Outcomes Research · 14.09.2026 · 26 (8) · 1097-1102
DOI: 10.1080/14737167.2026.2717293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 23.08.2026. Verfasst von Olga Pitsillidou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Unit of Global Health, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Macular Degeneration. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OBJECTIVE: In therapeutic classes characterized by outcome equivalence, the decision problem shifts from incremental cost-effectiveness to cost-neutral pricing. This study formalizes a break-even pricing framework, translating real-world utilization and costs into cost-neutral price thresholds, using anti-VEGF therapies for neovascular age-related macular degeneration (nAMD) as a case study. METHODS: A cost-minimization framework was applied from a public payer perspective in a single-payer system (Cyprus). Five anti-VEGF agents were evaluated over 3 years with 3.5% discounting. Injection frequencies were derived as weighted averages of treat-and-extend and pro re nata regimens from Phase 3/4 trials, with year 3 extrapolated from year 2. Break-even prices were defined as unit prices yielding equal discounted per-patient costs versus comparators. First-line thresholds used bevacizumab; second-line thresholds used a utilization-weighted comparator. Sensitivity analyses were conducted. RESULTS: Bevacizumab defined the lowest-cost benchmark (€4,130). Cost-neutral first-line use of newer agents required price reductions of 84-98%. Under second-line utilization, several agents fell below break-even thresholds at list prices. Key drivers were acquisition price, injection frequency, and monitoring costs. CONCLUSION: Break-even pricing generates explicit cost-neutral thresholds under outcome equivalence. While jurisdiction-specific, the framework is transferable and supports consistent pricing decisions in single-payer systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Unit of Global Health, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Pharmacy School, Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.
- Health Insurance Organization, Nicosia, Cyprus.
- Department of Economics, Econometrics and Finance, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands.
ORCID-Profile: Olga Pitsillidou, Panagiotis Petrou, M J Postma
Zitieren
APA
Pitsillidou, O., Petrou, P., & Postma, M. J. (2026). Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration. Expert Review of Pharmacoeconomics & Outcomes Research, 26(8), 1097-1102. https://doi.org/10.1080/14737167.2026.2717293
Vancouver
Pitsillidou O, Petrou P, Postma MJ. Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(8):1097-1102. doi:10.1080/14737167.2026.2717293
BibTeX
@article{Pitsillidou2026,
author = {Pitsillidou, Olga and Petrou, Panagiotis and Postma, M J},
title = {Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {8},
pages = {1097--1102},
doi = {10.1080/14737167.2026.2717293}
}
EUVIMED